share_log

iBio Inc | 8-K: Current report

iBio Inc | 8-K: Current report

iBio Inc | 8-K:重大事件
美股sec公告 ·  05/20 19:00
牛牛AI助理已提取核心訊息
On May 17, 2024, iBio Inc, through its subsidiary iBio CDMO LLC, entered into a definitive agreement with The Board of Regents of the Texas A&M University System to sell a property comprising land, improvements, and personal property for $8.5 million. The property sale is expected to close by May 31, 2024, subject to certain conditions. Concurrently, iBio CDMO amended its credit agreement with Woodforest National Bank, setting the term loan maturity to May 31, 2024, or earlier upon certain conditions. The outstanding balance of the term loan is approximately $13.1 million as of May 14, 2024. Additionally, iBio CDMO and iBio Inc have entered into a settlement agreement with the bank, agreeing to pay the sale proceeds from the property and issue a pre-funded warrant to the lender to cover the remaining balance. The warrant is exercisable for 1,560,570 shares of iBio Inc's common stock at a nominal price, equating to an indebtedness deficiency amount of approximately $4.5 million. The settlement will release both parties from any claims up to the closing date of the property sale.
On May 17, 2024, iBio Inc, through its subsidiary iBio CDMO LLC, entered into a definitive agreement with The Board of Regents of the Texas A&M University System to sell a property comprising land, improvements, and personal property for $8.5 million. The property sale is expected to close by May 31, 2024, subject to certain conditions. Concurrently, iBio CDMO amended its credit agreement with Woodforest National Bank, setting the term loan maturity to May 31, 2024, or earlier upon certain conditions. The outstanding balance of the term loan is approximately $13.1 million as of May 14, 2024. Additionally, iBio CDMO and iBio Inc have entered into a settlement agreement with the bank, agreeing to pay the sale proceeds from the property and issue a pre-funded warrant to the lender to cover the remaining balance. The warrant is exercisable for 1,560,570 shares of iBio Inc's common stock at a nominal price, equating to an indebtedness deficiency amount of approximately $4.5 million. The settlement will release both parties from any claims up to the closing date of the property sale.
2024年5月17日,iBio Inc通過其子公司iBio CDMO LLC與德克薩斯農工大學系統董事會達成最終協議,以850萬美元的價格出售包括土地、改善和個人財產在內的財產。此次房地產銷售預計將於2024年5月31日結束,但須遵守某些條件。同時,iBio CDMO修改了與伍德福里斯特國家銀行的信貸協議,將定期貸款的到期日定爲2024年5月31日,或在某些條件下更早。截至2024年5月14日,定期貸款的未償餘額約爲1,310萬美元。此外,iBio CDMO和iBio Inc已與該銀行簽訂了和解協議,同意支付該物業的出售收益,並向貸款人簽發預先注資的認股權證以彌補剩餘餘額。認股權證可按名義價格行使iBio Inc的1,560,570股普通股,相當於約450萬美元的負債赤字。該和解協議將解除雙方在房地產銷售截止日期之前的任何索賠。
2024年5月17日,iBio Inc通過其子公司iBio CDMO LLC與德克薩斯農工大學系統董事會達成最終協議,以850萬美元的價格出售包括土地、改善和個人財產在內的財產。此次房地產銷售預計將於2024年5月31日結束,但須遵守某些條件。同時,iBio CDMO修改了與伍德福里斯特國家銀行的信貸協議,將定期貸款的到期日定爲2024年5月31日,或在某些條件下更早。截至2024年5月14日,定期貸款的未償餘額約爲1,310萬美元。此外,iBio CDMO和iBio Inc已與該銀行簽訂了和解協議,同意支付該物業的出售收益,並向貸款人簽發預先注資的認股權證以彌補剩餘餘額。認股權證可按名義價格行使iBio Inc的1,560,570股普通股,相當於約450萬美元的負債赤字。該和解協議將解除雙方在房地產銷售截止日期之前的任何索賠。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。